Related Experiment Video
Updated: Feb 25, 2026
19:53
Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
Published on: March 1, 2015
106.5K
FACIAL PALSY - TREATMENT OPTIONS
A Ravikumar1, Prakash Singh2, V K Batish2
1Classified Specialist, ENT, Military Hospital Shillong, Meghalaya 793007.
Medical Journal, Armed Forces India
|August 5, 2017
Summary
Facial palsy management involves medical, surgical, and physical therapies. Combined approaches yield successful outcomes across varied etiologies, including Bell
Area of Science:
- Neurology
- Otolaryngology
Background:
- Facial palsy presents significant diagnostic and therapeutic challenges.
- Various medical, surgical, and physical treatment modalities exist for facial palsy.
Purpose of the Study:
- To present the management of 25 cases of facial palsy over a two-year period.
- To discuss diagnostic approaches, evaluation methods, and treatment outcomes for facial palsy.
Main Methods:
- Retrospective review of 25 facial palsy cases managed in a Neurotology clinic.
- Treatment modalities included medical management, facial nerve decompression, nerve approximation, nerve grafting, and hypoglossal facial anastomosis.
- All patients received physiotherapy; diagnostic evaluation involved clinical and electrodiagnostic tests.
Main Results:
- Bell's palsy cases showed an 83.5% recovery rate.
- Surgical decompression for CSOM-related facial palsy resulted in 100% recovery.
- Iatrogenic facial palsy had an 80% recovery rate, and post-tumor excision cases had a 68% recovery rate.
Conclusions:
- A combination of diagnostic and therapeutic strategies can successfully manage facial palsy.
- Treatment outcomes vary based on the etiology of facial palsy.
- Multimodal treatment, including surgery and physiotherapy, is crucial for optimizing facial palsy recovery.
Related Concept Videos
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:28Classification of Skeletal Muscle Relaxants
3.2K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.2K
01:20Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.7K